Business
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA reviewUpdated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis (MF) and anemia expected in H2 2026, followed by an End of Phase 2 MeetingInitial data from the ongoing Phase 2 study of DISC-3405 in polycythemia vera (PV) and Phase 1b study in sickle cell disease (SCD) expected in H2 2026 WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NAS
About this update from Disc Medicine, Inc.
[{"type":"image","alt":"Disc Medicine Inc","displaySize":"","headline":null,"caption":"Disc Medicine Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":46,"url":"https://media.zenfs.com/en/globenewswire.com/252ca54b96660d2e5211649d65d2516d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DUkrd_0R95Z67I1Tbxqz4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/252ca54b96660d2e5211649d65d2516d","width":300,"height":46}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA review","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"Updated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis (MF) and anemia expected in H2 2026, followed by an End of Phase 2 Meeting","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"Initial data from the ongoing Phase 2 study of DISC-3405 in polycythemia vera (PV) and Phase 1b study in sickle cell disease (SCD) expected in H2 2026","length":150,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":423,"olType":false},{"type":"text","content":"WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today outlined its recent pipeline progress and strategic priorities for 2026.","length":347,"tagName":"p"},{"type":"text","content":"“2025 was a transformative year for Disc, marked by strong execution across our portfolio and meaningful progress toward becoming a fully integrated clinical and commercial organization,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “Most notably, bitopertin received CNPV designation and we submitted our NDA under the accelerated approval pathway, positioning the NDA for rapid review by the FDA. We also reported positive initial Phase 2 data from the RALLY-MF study of DISC-0974 in anemia of myelofibrosis, demonstrating robust and broad hematologic activity, and advanced our third program DISC-3405 into proof-of-concept studies for polycythemia vera and sickle cell disease.”","length":715,"ta...